Promising early data for KITE-753 and azer-cel with IL-2 in R/R LBCL
Prof. Emmanuel Bachy discusses the latest findings for the autologous, rapid manufactured KITE-753 and allogeneic azer-cel in combination with interleukin-2.
Rapcabtagene autoleucel my be a viable frontline option in high-risk LBCL
Dr Jason Westin shares the latest findings on rapcabtagene autoleucel for the treatment of patients with high-risk large B-cell lymphoma autologous in the first-line setting.
Latest findings from the ATALANTA-1 trial of GLPG5101
Dr Pim Mutsaers discusses the latest findings from the ATALANTA-1 trial of GLPG5101, which uses a decentralized platform, in patients with R/R NHL.
CAR-T cell therapy in LBCL and immunotherapy highlights
Dr Eddie Cliff sets the scene for CAR-T cell therapy in LBCL and gives some of his immunotherapy highlights from the EHA2025 Congress in Milan, Italy.
